UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16
or 15d-16
Under the Securities Exchange Act of 1934
For the Month of August 2025
Commission File Number: 001-41084
NeuroSense Therapeutics Ltd.
(Translation of registrant’s name into English)
NeuroSense Therapeutics Ltd.
11 HaMenofim Street, Building B
Herzliya 4672562 Israel
+972-9- 7996183
(Address of principal executive offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
As of August 20, 2025, approximately 20% of people with ALS from the
Company’s Phase 2a study - including those continuing under compassionate use - remain on PrimeC for more than 5.5 years,
having lived with ALS for over 7 years. Across these multi-year exposures, treatment remains well tolerated, with no new safety signals
observed to date.
This
Report on Form 6-K (other than the third paragraph of Exhibit 99.1) is hereby incorporated by reference into registrant’s Registration
Statements on Form S-8 (File
No. 333-262480) and Form F-3 (File No. 333-269306, 333-260338, 333-283656 and 333-284051),
to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently
filed or furnished.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
NeuroSense Therapeutics Ltd. |
| |
|
|
| Date: August 20, 2025 |
By: |
/s/ Alon Ben-Noon |
| |
|
Alon Ben-Noon |
| |
|
Chief Executive Officer |
